Workflow
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
ABTAbbott(ABT) ZACKS·2025-03-24 13:45

Core Insights - The medical sector is increasingly adopting artificial intelligence (AI) for drug synthesis, precise measurement, and faster diagnosis [1] - AI applications in healthcare are enhancing diagnostics, treatment, and operational efficiency, with a projected market value of 95.65billionby2025[4]AIApplicationsinHealthcare−GenerativeAIandsurgicalroboticsarebeingutilizedindiagnosticsettingstodetectimageabnormalitiesthatmaybemissedbyhumaneyes[2]−AIisalsoimprovingelectronichealthrecords,predictiveanalytics,andreal−timealertingsystems[2]FocusonHealthcareGiants−FivehealthcarecompaniesarehighlightedfortheirextensiveAIapplications:Medtronicplc(MDT),EliLillyandCo.(LLY),BostonScientificCorp.(BSX),NovartisAG(NVS),andAbbottLaboratories(ABT)[3][6]Company−SpecificInsightsMedtronicplc(MDT)−MDTisintegratingAIintosurgicalsystemsandhasdevelopedanAI−poweredsurgicalvideomanagementplatform[8]−TheGIGeniusprojectenhancescolorectalcancerdetection,increasingsurvivabilitybyidentifyingpolyps[9]−ExpectedrevenueandearningsgrowthratesforMDTare3.495.65 billion by 2025 [4] AI Applications in Healthcare - Generative AI and surgical robotics are being utilized in diagnostic settings to detect image abnormalities that may be missed by human eyes [2] - AI is also improving electronic health records, predictive analytics, and real-time alerting systems [2] Focus on Healthcare Giants - Five healthcare companies are highlighted for their extensive AI applications: Medtronic plc (MDT), Eli Lilly and Co. (LLY), Boston Scientific Corp. (BSX), Novartis AG (NVS), and Abbott Laboratories (ABT) [3][6] Company-Specific Insights Medtronic plc (MDT) - MDT is integrating AI into surgical systems and has developed an AI-powered surgical video management platform [8] - The GI Genius project enhances colorectal cancer detection, increasing survivability by identifying polyps [9] - Expected revenue and earnings growth rates for MDT are 3.4% and 5%, respectively [11] Eli Lilly and Co. (LLY) - LLY focuses on cardiometabolic health, neuroscience, oncology, and immunology, with a strong portfolio in diabetes treatment [12][13] - The company collaborates with OpenAI and invested 409 million in Genetic Leap for AI-driven drug discovery [14] - Expected revenue and earnings growth rates for LLY are 33% and 80.7%, respectively [15] Boston Scientific Corp. (BSX) - BSX is investing in AI-driven health IT solutions to enhance healthcare delivery and clinical outcomes [16] - The company is also focusing on AI-enhanced medical education tools and patient engagement solutions [17] - Expected revenue and earnings growth rates for BSX are 13.8% and 13.6%, respectively [18] Novartis AG (NVS) - NVS is applying AI in generative chemistry, AE brain, and AI nurse applications to innovate patient technologies [19][20] - Expected revenue and earnings growth rates for NVS are 4.1% and 8.5%, respectively [21] Abbott Laboratories (ABT) - ABT utilizes AI for advanced medical imaging and predictive algorithms for heart attack prevention [22] - The company holds a strong position in point-of-care testing across various healthcare areas [23] - Expected revenue and earnings growth rates for ABT are 5.7% and 10.3%, respectively [23]